Edgewise Therapeutics, Inc. (EWTX) 10-Year Financial Performance & Capital Metrics

EWTX • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutEdgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Show more

Revenue $0
EBITDA -$157M -39.0%
Net Income -$134M -33.6%
EPS (Diluted) -1.45 +7.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -34.4% -14.3%
ROIC -36.07% -19.3%
Debt/Equity 0.01 -39.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 88 (top 12%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 45.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-26.51%

EPS CAGR

10Y-

5Y-

3Y-

TTM-5.33%

ROCE

10Y Avg-30.68%

5Y Avg-28.34%

3Y Avg-32.42%

Latest-40.4%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	123K	185K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-123K	-185K	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-0.5%	1%	-	-	-
Operating Expenses+	9.92M	17.01M	43.22M	71.66M	114.36M	158.83M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	1.3M	2.21M	11.03M	17.63M	23.45M	31.87M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	8.62M	14.8M	32.19M	54.03M	90.91M	126.97M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-9.92M	-17.19M	-43.22M	-71.66M	-114.36M	-158.83M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.73%	-1.51%	-0.66%	-0.6%	-0.39%
EBITDA+	-9.8M	-17.01M	-42.94M	-71.12M	-112.63M	-156.54M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-0.74%	-1.53%	-0.66%	-0.58%	-0.39%
D&A (Non-Cash Add-back)	123K	185K	272K	538K	1.73M	2.29M
EBIT	-9.92M	-17.19M	-43.22M	-71.66M	-114.36M	-158.83M
Net Interest Income+	219K	69K	402K	-1.35M	14.19M	25.02M
Interest Income	219K	69K	402K	2.66M	14.19M	25.02M
Interest Expense	0	0	0	4.02M	0	0
Other Income/Expense	219K	69K	402K	4.02M	14.19M	25.02M
Pretax Income+	-9.71M	-17.12M	-42.81M	-67.64M	-100.16M	-133.81M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	0.98%	1%	1%	1%	1%	1%
Net Income+	-9.49M	-17.05M	-42.81M	-67.64M	-100.16M	-133.81M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.8%	-1.51%	-0.58%	-0.48%	-0.34%
Net Income (Continuing)	-9.71M	-17.12M	-42.81M	-67.64M	-100.16M	-133.81M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.19	-0.35	-0.86	-1.26	-1.57	-1.45
EPS Growth %	-	-0.84%	-1.46%	-0.47%	-0.25%	0.08%
EPS (Basic)	-0.19	-0.35	-0.86	-1.26	-1.57	-1.45
Diluted Shares Outstanding	49.22M	49.22M	49.5M	53.59M	63.72M	92.41M
Basic Shares Outstanding	49.22M	49.22M	49.5M	53.59M	63.72M	92.41M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	24.04M	129.65M	283.77M	357M	327M	475.48M
Cash & Short-Term Investments	23.65M	129.09M	280.79M	351.95M	318.39M	470.17M
Cash Only	23.65M	104.92M	15.57M	21.99M	86.1M	41.67M
Short-Term Investments	0	24.18M	265.22M	329.95M	232.3M	428.5M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	0	8.6M	5.31M
Total Non-Current Assets+	498K	1.49M	1.46M	10.1M	13.04M	11.33M
Property, Plant & Equipment	498K	516K	912K	9.85M	12.69M	11.07M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	975K	548K	251K	348K	262K
Total Assets+	24.54M	131.14M	285.23M	367.1M	340.04M	486.82M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	4.34%	1.18%	0.29%	-0.07%	0.43%
Total Current Liabilities+	1.13M	4.34M	10.52M	16.59M	16.77M	23.86M
Accounts Payable	667K	1.58M	3.84M	6.11M	4.03M	5.58M
Days Payables Outstanding	1.98K	3.12K	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	333K	452K	2.8M	4.03M	5.7M	10.06M
Current Ratio	21.24x	29.86x	26.97x	21.53x	19.50x	19.93x
Quick Ratio	21.24x	29.86x	26.97x	21.53x	19.50x	19.93x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	40.26M	160.21M	329K	3.8M	4.43M	3.74M
Long-Term Debt	0	160.21M	0	0	0	0
Capital Lease Obligations	0	0	0	3.8M	4.43M	3.74M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	40.26M	0	329K	0	0	0
Total Liabilities	41.39M	164.56M	10.85M	20.39M	21.2M	27.6M
Total Debt+	0	160.21M	0	4.41M	5.41M	4.74M
Net Debt	-23.65M	55.3M	-15.57M	-17.59M	-80.68M	-36.93M
Debt / Equity	-	-	-	0.01x	0.02x	0.01x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-17.83x	-	-
Total Equity+	-16.85M	-33.42M	274.38M	346.72M	318.83M	459.22M
Equity Growth %	-	-0.98%	9.21%	0.26%	-0.08%	0.44%
Book Value per Share	-0.34	-0.68	5.54	6.47	5.00	4.97
Total Shareholders' Equity	-16.85M	-33.42M	274.38M	346.72M	318.83M	459.22M
Common Stock	0	0	5K	6K	7K	9K
Retained Earnings	-17.02M	-34.15M	-76.96M	-144.6M	-244.76M	-378.58M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-514K	-1.35M	99K	420K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.17M	-14.63M	-33.51M	-52.63M	-91.95M	-109.03M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.6%	-1.29%	-0.57%	-0.75%	-0.19%
Net Income	-9.71M	-17.12M	-42.81M	-67.64M	-100.16M	-133.81M
Depreciation & Amortization	123K	185K	272K	538K	1.73M	2.29M
Stock-Based Compensation	77K	354K	4.4M	10.92M	17.56M	24.71M
Deferred Taxes	0	0	-2.29M	0	0	0
Other Non-Cash Items	0	0	2.29M	-543K	-9.52M	-12.54M
Working Capital Changes	334K	1.95M	4.63M	4.09M	-1.56M	10.33M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	275K	521K	2.65M	47K	-92K	1.74M
Cash from Investing+	-180K	-24.38M	-242.23M	-70.58M	102.89M	-184.66M
Capital Expenditures	-180K	-203K	-668K	-5.55M	-5.75M	-1.31M
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	-241.56K	-65.03K	0	0
Cash from Financing+	24.8M	120.28M	186.38M	129.64M	53.17M	249.25M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	22K	202K	236K	474K	548K	10.11M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-9.35M	-14.84M	-34.17M	-58.18M	-97.69M	-110.34M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.59%	-1.3%	-0.7%	-0.68%	-0.13%
FCF per Share	-0.19	-0.30	-0.69	-1.09	-1.53	-1.19
FCF Conversion (FCF/Net Income)	0.97x	0.86x	0.78x	0.78x	0.92x	0.81x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-35.53%	-21.78%	-30.1%	-34.4%
Return on Invested Capital (ROIC)	-	-	-23.09%	-18.28%	-30.24%	-36.07%
Debt / Equity	-	-	-	0.01x	0.02x	0.01x
Interest Coverage	-	-	-	-17.83x	-	-
FCF Conversion	0.97x	0.86x	0.78x	0.78x	0.92x	0.81x

Frequently Asked Questions

Growth & Financials

Edgewise Therapeutics, Inc. (EWTX) grew revenue by 0.0% over the past year. Growth has been modest.

Edgewise Therapeutics, Inc. (EWTX) reported a net loss of $157.2M for fiscal year 2024.

Dividend & Returns

Edgewise Therapeutics, Inc. (EWTX) has a return on equity (ROE) of -34.4%. Negative ROE indicates the company is unprofitable.

Edgewise Therapeutics, Inc. (EWTX) had negative free cash flow of $132.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener